skip to Main Content
Issue Areas
Events
Publications
Connect With Us
About Us
2022 Snapshot
About IHP
Meet the Team
Contributing Authors
Search
Menu
Search
Submit
Issue Areas
Drug Policy
Prescription drug prices continue to rise, threatening to make vital therapies unaffordable for many patients.
Learn more
As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is critical for policymakers to understand the root causes and potential solutions.
Focus areas
Fostering Competitive Markets
High-Value Therapies for Patients
Featured content
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Publications from PORTAL
Restoring Provider Confidence In FDA-Approved Drugs
Evolving nature of evidence required by FDA to approve new drugs
Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
Building a bigger table for a more equitable drug development system
The Medicaid Drug Rebate Program and the impact of “best price” rules
Drug policy 101: Pharmaceutical marketing tactics
The promise — and challenges — of gene therapy
Determining drug value: Let’s start with the evidence
Drug policy 101: Breaking down different types of drug products
Driving the conversation on drug value
How to save the patent system in 3 easy steps
It’s time to change drug companies’ harmful marketing practices
The price Is wrong: Why we need to curb prices on biologics to protect patients
A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug policy 101
Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
Drug policy 101: Pharmaceutical marketing tactics
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Drug policy 101: Drug patents
Drug policy 101: Biosimilars
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug Policy 101: Pay-for-delay
Events
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
Building Racial Equity into the Drug Development System
Unpacking Drug Value
Addressing High Drug Pricing
Presenters
Rojelio Mejia, MD
Assistant professor of infectious diseases and pediatrics, National School of Tropical Medicine, Baylor College of Medicine
Uriridiakoghene “Ulili” Onovakpuri, MBA
Partner, Kapor Capital
Hannah Valantine, MD
Stanford Medicine, Professor of Medicine Former NIH Chief Scientific Officer for Scientific Workforce Diversity
Harriet A. Washington
Writing fellow, bioethics, Harvard Medical School; fellow, New York Academy of Medicine
Back To Top
Search
Submit
Subscribe
No, thanks
CLOSE